Antibody-drug conjugates: an emerging modality for the treatment of cancer

Ann N Y Acad Sci. 2014 Aug;1321:41-54. doi: 10.1111/nyas.12499.

Abstract

Antibody-drug conjugates (ADCs) offer promise as a therapeutic modality that can potentially reduce the toxicities and poor therapeutic indices caused by the lack of specificity of conventional anticancer therapies. ADCs combine the potency of cytotoxic agents with the target selectivity of antibodies by chemically linking a cytotoxic payload to an antibody, potentially creating a synthetic molecule that will deliver targeted antitumor therapy that is both safe and efficacious. The ADC repertoire contains a range of payload molecules, antibodies, and linkers. Two ADC molecules, Kadcyla® and Adcetris®, have been approved by the FDA, and many more are currently in clinical development.

Keywords: antibody-drug conjugate; cancer therapy; linker; payload; quantitative translational systems pharmacology.

Publication types

  • Review

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Brentuximab Vedotin
  • Drug Approval
  • Drug Design
  • Humans
  • Immunoconjugates / chemistry
  • Immunoconjugates / therapeutic use*
  • Maytansine / analogs & derivatives
  • Maytansine / therapeutic use
  • Molecular Targeted Therapy / trends*
  • Neoplasms / drug therapy*
  • Trastuzumab
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Immunoconjugates
  • Maytansine
  • Brentuximab Vedotin
  • Trastuzumab
  • Ado-Trastuzumab Emtansine